Psilocybin may link with short-term gains in some groups. These gains involve attention and flexible thinking. The review did not show a sure benefit for all. The studies were small, early, and uneven. (1, 2) Psilocybin is a compound found in some mushrooms. Cognitive flexibility means shifting your thinking when life changes.

These findings can matter if your mind feels stuck. Depression, anxiety, and trauma can narrow thought. So can long stress and poor sleep. Headlines about “rewiring the brain” can feel exciting. They can also leave out key facts. It helps to ask who was studied. It helps to ask what the tests measured. It also helps to ask what was not shown. This article explains the review in plain terms. It also keeps the safety frame in view.

What did the new review find about psilocybin and cognition?

The review found the clearest signal with psilocybin. The gains came after the main drug effects ended. They appeared most often in attention and cognitive flexibility. The authors still called the proof early. (1)

The review covered 67 clinical and preclinical studies. Clinical studies involve people. Preclinical studies often use cells or animals. The review examined classic psychedelics, MDMA, and ketamine. It looked for thinking changes after at least one day. The authors wanted changes beyond the acute drug state. Acute means the short time when effects are strongest. 

Psilocybin stood out more than other drugs. Ketamine had mixed results across thinking tasks. LSD and DMT did not show steady later changes. MDMA sometimes linked with short-term thinking problems. In the reviewed studies, those problems often faded within days. (1) A psychedelic can shift mood, thought, and perception for a time.

The most useful point is modest. Psilocybin may affect some thinking skills after use. That signal is not yet firm proof. It is also not proof of better daily function. A lab task is not the same as life. People still need larger and stronger studies. They also need clearer reports of harms and gains.

Does psilocybin make healthy people smarter?

No. Studies do not show that psilocybin makes healthy people smarter. They also do not show faster thinking for healthy people. Most benefit signals appeared in clinical groups. (1, 2)

A 2024 review looked at 20 studies. Those studies included 2,959 people. In healthy volunteers, broad cognition often did not change. Processing speed often did not change either. Some studies in treatment-resistant depression showed gains. These gains involved attention, working memory, and executive function. Some gains also involved emotional processing. (2) Treatment-resistant depression means depression that did not improve after several treatments. 

This difference matters when reading news. Feeling clearer after depression lifts can be real. It can also be deeply important. But that is not the same as a brain boost. It may reflect relief from symptoms. It may reflect better sleep or less rumination. It may reflect hope, support, or time.

Many things can harm clear thinking. Depression can slow focus. Anxiety can pull attention toward threat. Trauma can keep the body on alert. Grief can make memory feel weak. Medicines can affect energy and focus. Medical conditions can also play a role. One study result cannot explain every cause. It also cannot predict your personal response.

What does cognitive flexibility mean?

Cognitive flexibility means changing thoughts or actions when old patterns fail. It is a useful skill in daily life. It may matter in depression, anxiety, and trauma.

For example, a person may get stuck in worry. Another person may repeat harsh self-talk. Someone else may avoid hard tasks again and again. Flexible thinking can help people notice more choices. It can help them test a new response. It does not mean all pain vanishes. It means the mind has more room to move. 

One small 2021 study followed 24 people. They all had major depression. They received psilocybin therapy in an open-label trial. Open-label means people knew what they received. They made fewer repeated errors on a set-shifting task. The change lasted at least four weeks. But there was no placebo group. The thinking change did not match mood change neatly. So the result is interesting, not final. (3)

If you see broad claims, context matters. Our earlier post gives more background. See Psilocybin Can Actually Boost Your Brain Power. Lasting change often needs more than one event. Sleep, stress, and support shape thinking. So do relationships and trauma history. A drug effect is only one possible piece.

Why should Texans be cautious about “brain-boosting” claims?

Promising research is not a personal treatment plan. Trials use screening, support, and follow-up. They also use clear safety steps. Those steps are part of the study. (4)

Psychedelic trials are not casual settings. Researchers screen for health risks. They prepare people before sessions. They monitor people during sessions. They also follow people afterward. Some people may be excluded or watched more closely. That matters when results are shared in headlines. 

The FDA’s 2026 guidance notes special study needs. It highlights design and safety issues for psychedelic trials. (4) The National Center for Complementary and Integrative Health also urges care. It notes that psilocybin experiences can vary widely. Some may include fear, anxiety, and confusion. They may also include changes in perception. (5) Risk can change by person, setting, and health. Other substances can change risk too.

Research interest is not a reason to self-treat. It is also not proof of safe use. If depression, anxiety, or trauma narrows your thinking, support can help. Psychedelic integration support can help people process past experiences. Anxiety therapy can address worry and rumination that harm attention.

What is the bottom line on psilocybin and cognitive benefits?

The new review gives a careful reason for interest. It does not give a final answer. Psilocybin showed the most steady later signal. The gains were mainly attention and flexible thinking. (1)

The limits are just as important. The studies were small. Their reports were uneven. Results looked stronger in clinical groups. They looked weaker in healthy volunteers. (1) This may mean symptoms improved first. It may not mean people gained new brain power. 

It is normal to feel curious. It is also wise to stay cautious. A treatment may one day help mental rigidity. It may help some fog linked with depression. Still, the honest stance holds two truths. The science is moving. The conclusions are not settled.

We offer evidence-based support for hard questions. These may involve depression, anxiety, trauma, or psychedelic experiences. You will not be pushed toward a quick answer. If you want a thoughtful talk about this research, schedule a free consultation with Jeff Jones, LPC. 

About the Author: This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice since 1999. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life's challenges and find a path toward healing. 

Disclaimer: The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. 

References

1.Kelly, C., Cooley, B. J., Zeng, L., Hurzeler, T., Manning, V., McNally, G. P., Watt, J., Haber, P. S., & Morley, K. C. (2026). Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence. Neuroscience & Biobehavioral Reviews, 190, 106911. https://doi.org/10.1016/j.neubiorev.2026.106911

2.Meshkat, S., Tello-Gerez, T. J., Gholaminezhad, F., et al. (2024 ). Impact of psilocybin on cognitive function: A systematic review. Psychiatry and Clinical Neurosciences, 78(12), 744–764. https://doi.org/10.1111/pcn.13741

3.Doss, M. K., Považan, M., Rosenberg, M. D., et al. (2021 ). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11, 574. https://doi.org/10.1038/s41398-021-01706-y

4.U.S. Food and Drug Administration. (2026, July ). Psychedelic drugs: Considerations for clinical investigations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

5.National Center for Complementary and Integrative Health. (n.d. ). Psilocybin for mental health and addiction: What you need to know. National Institutes of Health. https://www.nccih.nih.gov/health/psilocybin-for-mental-health-and-addiction-what-you-need-to-know